Hamburg (ots) - Philipp Lurz (35) ist ab sofort stellvertretender Vertriebsleiter bei der dpa-Tochter news ...
Accuray CE Marks Its New Radixact(TM) System
Sunnyvale, California (ots/PRNewswire) - Next Generation Image-Guided Radiation Therapy Platform and Integrated Software Solutions are Now Available for Use by Clinicians in the European Union
Accuray Incorporated (NASDAQ: ARAY) announced today that it has CE marked its Radixact(TM) Treatment Delivery System, Accuray Precision(TM) Treatment Planning System and iDMS(TM) Data Management System. The next generation hardware and software solutions, together, make up the new Radixact platform, which represents a major step forward in the evolution of Accuray's existing TomoTherapy® System in treatment speed and ease of use. The platform will now be available in certain markets in the European Union (EU), in addition to the U.S. market where it received FDA 510(k) clearance in June 2016.
The Radixact System is a "smart" system that will enable faster, more efficient delivery of extremely precise treatment to a wider range of cancer patients across the European market. It features a more powerful linear accelerator, MVCT imaging and helical treatment delivery, so clinicians can apply highly conformal and homogeneous dose distributions to any target volume, while precisely sparing normal healthy tissue during each treatment fraction.
"Radixact System availability in the EU is a critical component of our commercial launch strategy for this innovative platform," said Joshua H. Levine, president and chief executive officer of Accuray. "We have shipped the first commercially released Radixact System to a site in the U.S. and expect our first EU shipment during our Fiscal Q1 2017. The system is a key driver of our short- and long-term growth outlook, as well as our ability to achieve sustainable profitability, and we are excited about the reception the system is receiving in the marketplace."
The Radixact platform is comprised of three entirely new, transformative technologies:
- Radixact Treatment Delivery System: Taking the industry-leading capabilities of the TomoTherapy Systems to a new level. - Accuray Precision Treatment Planning System: Smart, automated workflows and mid-course decision-making tools that enable clinicians to adapt delivery according to changes in tumor size, shape and location. - iDMS Data Management System: Seamless management of patient data across multiple Radixact Systems and clinics, from a single point of control.
For Important Safety information about radiotherapy please refer to: http://www.accuray.com/safety-statement-radiation-treatment.
For more information about the Radixact platform, visit: http://www.accuray.com/radixact.
Accuray Incorporated (NASDAQ: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit http://www.accuray.com .
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, regulatory approvals and launches of new products, market uptake of recently launched products, and Accuray's leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed from time to time under the heading "Risk Factors" in the company's report on Form 10-K, filed on August 28, 2015, the company's reports on Form 10-Q, filed on November 5, 2015, February 1, 2016 and April 29, 2016, and the company's other filings with the SEC.
Forward-looking statements speak only as of the date the statements are made and are based on information available to Accuray at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.